baber/WOPTO huggingface dataset:
Patent NZ-509260-A (NZ)
Title: Pharmaceutical composition containing valsartan and a calcium channel blocker
Inventor: DE GASPARO MARC
IPC: A61K31/4184
Filed: 1999-07-09
Abstract: Described is a pharmaceutical combination  composition comprising: i)    the  AT1-antagonist  valsartan or  a  pharmaceutically acceptable salt thereof and ii)   a  calcium  channel blocker selected  from  a  non-DHP representative   or  a  pharmaceutically   acceptable   salt thereof, and iii) a pharmaceutically acceptable carrier. Also described is the use of a combination of: i)    the  AT1-antagonist  valsartan or  a  pharmaceutically acceptable salt thereof and ii)    a  calcium  channel  blocker  or  a  pharmaceutically acceptable salt thereof for  the  manufacture of a medicament for the  treatment  or prevention  of diabetes, hypertension in diabetic  patients, for  slowing the progression of diabetic renal diseases,  or for reducing proteinurea in diabetic patients.
Patent NZ-509640-A (NZ)
Title: Selection of communication channels using pseudo random processes which are coordinated between the nodes
Inventor: HORN CLIVE DOUGLAS
IPC: H04L12/00
Filed: 2001-01-30
Abstract: Usually, channel selection is performed by a central control. To avoid this, a method is proposed where the multiple mobile nodes can communicate with one another without the need of central control. To do this, a similar number generator, for example a pseudorandom number generator, is used at all the mobile nodes. To determine which channel to use, the number generators are invoked using a common seed. This will then produce a common output. The output represents which channel the transmission and reception will happen. Initially, the transmission to specific node will occur by using its identifier. So, if node A was to communicate with node B, A would dial the number of node B, which is known, and this number/identifier is associated with a default channel which node B always 'listens' to. Once this initial communication is set up, the channel is allocated through the number generator process.
Patent NZ-512818-A (NZ)
Title: Process for preparing anti-cancer quinazoline compounds
Inventor: SANTAFIANOS DINOS PAUL
IPC: C07D405/00
Filed: 2000-03-30
Abstract: A compound of formula 9 is prepared by reacting a compound of formula 10 with a primary alcohol of the formula R7-OH in the presence of an alkali-metal or alkaline-metal hydroxide R7 is C1-C10 or -(C1-C6 alkyl)(C6-C10 aryl) optionally substituted by 1 to 3 substituents independently selected from halo, nitro, trifluoromethyl, trifluoromethoxy, alkylsulfonyl, alkyl, alkoxy, aryloxy and arylsulfonyl. In formula 9 and 10 R6 is alkyl or -(CH2)mO(CH2)nCH3 m is independently an integer from 1 to 6 and n is an integer from 0 to 3 R7 is -alkyl or -alkylaryl optionally substituted with 1-3 substituents independently selected from halo, nitro, trifluoromethyl, trifluoromethoxy, alkylsulfonyl, alkyl, alkoxy, aryloxy and arylsulfonyl. R8, R9 and R10 are each independently selected from H, alkyl, halo, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, aziod, OR11, -C(O)R11, C(O)R11, -NR12C(O)OR14, -OC(O)R11, -NR12SO2R14, -SO2NR11R12, -NR12C(O)R11, -C(O)NR11R12, -NR11R12, -S(O)j(CH2)q(C6-C10 aryl), -NR12(CH2)q(C6-C10 aryl) and -(CH2)q(4-10 membered heterocyclic. The alkyl, aryl and heterocyclic groups can be optionally substituted by 1 to 5 substituents. R11 is independently selected from H, alkyl, -(CH2)q(C6-C10 aryl), and -(CH2)q(4-10 membered heterocyclic) and can be optionally substituted by 1 to 5 substituents. R12 is independently H or alkyl R15 is H, alkyl or -(CH2)q(C6-C10 aryl) q is an integer from 0 to 4 , and j is an integer from 0 to 2
Patent NZ-514238-A (NZ)
Title: Device for preventing explosions in electrical transformers
Inventor: MAGNIER PHILIPPE
IPC: H01F27/00
Filed: 2000-03-17
Abstract: A device for preventing explosions in an electrical transformer comprising a vessel filled with a fuel cooling fluid, and means for decompressing the transformer vessel. The decompressing means comprise a rupture element (1) with an incorporated explosion detector provided with a retaining part (4) including first zones with reduced thickness relative to the rest of the retaining element (4) and capable of being torn off without being fragmented when said element (1) is ruptured, and second zones with reduced thickness relative to the rest of the retaining element (4) and capable of bending without getting torn off when said element (1) is ruptured. Said rupture element (1) is capable of being ruptured when the pressure inside the vessel exceeds a predetermined ceiling. The signal of the explosion detector integrated in the rupture disc triggering a cooling system and preventing oxygen from coming in contact with the explosive gases generated by the electric arc by contact with oil.
Patent NZ-515952-A (NZ)
Title: Tamper-evident form, typically pay slip, with additional perforations that make it difficult to open form without tearing perforations
Inventor: BRANAGAN JOHN
IPC: B65D27/30
Filed: 2001-12-04
Abstract: A form (10) suitable to use as an envelope, the form (10) including: at least one planar sheet including adhesive for adhering portions of the sheet together so that the form can be used to provide a sealed envelope having an inaccessible portion; a primary frangible means including perforated lines (110, 120) which, when broken, allows access to the inaccessible portion of the envelope; and an additional frangible means including one or more perforated lines (142, 144, 146) that extend inwardly from the edge of at least one side of the form, which represents a tamper-evident feature difficult to avoid breaking when illegitimately attempting to gain access to the inaccessible portion of the envelope.
Patent NZ-517041-A (NZ)
Title: Method for preparing quinoline-5,8-diones
Inventor: COSSY JANINE
IPC: C07D215/48
Filed: 2000-08-10
Abstract: The invention concerns a method for preparing quinoline- 5,8-diones  of  formula (I) wherein R1, R2  and  R3  are  as defined  in claim 1, by light-induced oxygenation  of  a  8- hydroxyquinoline.
Patent NZ-518109-A (NZ)
Title: Method and apparatus for installing a fitting
Inventor: BURGESS JOHN DAVID TILBURY
IPC: E04F19/08
Filed: 2000-09-22
Abstract: The present invention regards a box to be embedded  for the  housing of switches and current taps, provided  with  a cover  consisting  of a plastic rectangular  plate  suitable for  fitting exactly inside the box mouthpiece.  Said  cover has  two  couples of crooked teeth, obtained  while  molding and  overhanging from its internal face in such  a  position to  allow  the  hooking of the wings to  the  metal  inserts where the terminal strip is screwed.
Patent NZ-518948-A (NZ)
Title: New alpha-amino-acid compounds, a process for their preparation and pharmaceutical compositions containing them
Inventor: DE NANTEUIL GUILLAUME
IPC: C07D277/04
Filed: 2002-05-14
Abstract: A compound of formula (I) wherein; NA represents a 5-membered nitrogen containing heterocycle optionally substituted by a cyano group; Ak represents an alkylene chain; X represents a single bond or a phenylene group; R1 and R2 each represent H or alkyl; Y represents NR4 or CH-NO2, where R4 is H or alkyl; R3 represents alkyl, nitro or cyano when Y represents CH-NO2 or cyano or nitro when Y is NR4. Also described are pharmaceutical compositions containing formula (I) and a process for making it.
Patent NZ-520752-A (NZ)
Title: Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
Inventor: SMITH STEPHEN ALLAN
IPC: C07D239/70
Filed: 2001-02-13
Abstract: Disclosed is the compound 1-(N-(2-(Diethylamino)ethyl)- N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2- (4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one, of formula 1, a method for the compounds production and the use of the compound in the manufacture of a medicament for treating a disease associated with the enzyme Lp-PLA2.
Patent NZ-522144-A (NZ)
Title: Electrical connector with contact parts which are set apart from each other
Inventor: JOHNSTON GLEN
IPC: H01R24/64
Filed: 2001-04-25
Abstract: An electrical connector (8) comprising at least four long conductive elements (16, 18, 20, 22) which each extend between a first contact (30) at one end and a second contact (28) at the other end. Sections (44) of the conductive elements have recessed parts (42) in order to increase the distance between adjacent pairs (20, 16; 18, 22) of the conductive elements at points next to the second contacts (28).
Patent NZ-523269-A (NZ)
Title: Catalyst and process for the preparation of hydrocarbons
Inventor: GEERLINGS JACOBUS JOHANNES COR
IPC: B01J23/89
Filed: 2001-06-29
Abstract: Described is a process for the production of mainly C5+ hydrocarbons comprising contacting carbon monoxide and hydrogen at a temperature in the range of from 180 to 270oC and elevated pressure in the presence of a catalyst. Also described is a catalyst composition comprising cobalt, manganese and rhenium on a titania carrier.
Patent NZ-524893-A (NZ)
Title: Method for producing a solid herbicide formulation
Inventor: JAGER KARL-FRIEDRICH
IPC: A01N43/88
Filed: 2001-08-30
Abstract: In a process for the preparation of a solid herbicidal formulation comprising: (a) a herbicide from the group of the sulfonylureas or their agriculturally useful salts, (b) with or without one or more further herbicides, (c) with or without a safener, (d) one or more formulation auxiliaries, wherein the process comprises suspending the sulfonylurea (a) with or without one or kore further herbicides (b) and with or without a safener (c) and one or more formulation auxiliaries (d) in water to give a suspension, bringing the suspension to pH 6.5 to 8.0, by adding an acid or base and drying it to give a solid formulation.
Patent NZ-528115-A (NZ)
Title: Camptothecin (CPT) derivatives for treating various types of cancer
Inventor: YANG LI-XI
IPC: A61K31/5377
Filed: 2002-02-06
Abstract: (20S) esters of camptothecin analogues are provided. The compounds are (20S) esters of an aminoalkanoic acid or an imidoalkanoic acid and camptothecin, which are optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. These compounds are useful for treating cancer.
Patent NZ-528984-A (NZ)
Title: Cabinet lock with selective interference means to prevent bolt/striker coupling
Inventor: NYE-HINGSTON MATTHEW RICHARD A
IPC: E05B65/462
Filed: 2003-10-17
Abstract: Disclosed is a bolt and striker cabinet lock assembly. The bolt is normally urged to a locking position but can be retracted (typically electromagnetically). An interference means, typically a slider is provided so as to selectively block the striker aperture and prevent coupling of bolt and striker.
Patent NZ-532439-A (NZ)
Title: Freight container
Inventor: DEWINTER UWE
IPC: B65D90/54
Filed: 2004-04-21
Abstract: A freight container has doors at one end of different widths but the same height. The larger door has a latch by which that door can be opened through one unlatching operation. The smaller door has no external latch but is locked internally.
Patent NZ-533042-A (NZ)
Title: Filler for the manufacture of base paper and method for the manufacture of base paper
Inventor: LESKELA MARKKU
IPC: D21H11/10
Filed: 2002-11-21
Abstract: The use of precipitated calcium carbonates (PCC) as fillers for the manufacture of base paper together with mechanical hardwood pulp and chemical softwood pulp. Also described is a method for the manufacture of base paper, in which method pulp produced from hard woods, in particular from the wood of the genus Populus, and chemical softwood pulp are used together with a PCC filler.
Patent NZ-533712-A (NZ)
Title: Injection solution comprising an LHRH antagonist
Inventor: SARLIKIOTIS WERNER
IPC: A61K47/26
Filed: 2002-11-15
Abstract: The following alternative processes for the preparation of aqueous solutions of an LHRH antagonist lead to an increase in the bioavailability, and make possible the lowering of the injection volume to be administered. a) an LHRH antagonist, an organic, physiologically tolerable acid and optionally a surfactant and a bulking agent are dissolved in water for injection, homogenized and processed for injection purposes; or b) an LHRH antagonist and optionally a surfactant and a bulking agent are dissolved using an aqueous saturated solution of an organic, physiologically tolerable acid, homogenizes and processed for injection purposes. The LHRH is disclosed to be selected from teverelix, D-63153, abarelix and azaline B. The solution, which also contains Tween 80 and mannitol, is adjusted to a pH of around 2.5 using an aqueous, saturated gluconic acid delta-lactone solution.
Patent NZ-534984-A (NZ)
Title: Uses of compounds for the treatment of pancreatic disease
Inventor: KELLY LYNDELL E
Filed: 2000-08-30
Abstract: The use of cyanohydroxybutene in the manufacture of a medicament to treat pancreatic cancer by inducing acinar cell apoptosis with a lack of regeneration. Also disclosed is the use of cyanohydroxybutene to treat pancreatitis.
Patent NZ-537752-A (NZ)
Title: Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
Inventor: SINGH RAJINDER
IPC: A61P37/00
Filed: 2003-07-29
Abstract: Disclosed herein is a use of 2,4-pyrimidinediamine compounds of formula (I) in the preparation of a medicament for the treatment of an autoimmune diseases selected from autoimmune disease is selected from the group consisting of Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis and membranous glomerulopathy, wherein the variables shown in formula (I) are as defined in the specification.
Patent NZ-541698-A (NZ)
Title: Selecting animals for desired genotypic or potential phenotypic properties based on a single nucleotide polymorphism (snp) in intron 3 of the IGF2 gene
Inventor: ANDERSSON LEIF
IPC: C12Q1/68
Filed: 2004-01-09
Abstract: A method for selecting a domestic animal having desired genotypic or potential phenotypic properties i.e. muscle mass, fat deposition, or teat numbers comprising testing the animal, a parent of the animal or its progeny for the presence of a nucleic acid modification affecting the binding of a nuclear factor to an IGF2 gene, wherein the nuclear factor is capable of binding to a stretch of nucleotides which in the wild type pig, mouse or human IGF2 gene is part of an evolutionary conserved CpG island, located in intron 3 of the IGF2 gene. Also described are in vitro methods for identifying a compound capable of modulating mRNA transcription of an IFG2 gene in a cell of an animal or an organism provided with the IGF2 gene, a compound comprising a functionally equivalent oligonucleotide or analogue to the sequence: 5'-GATCCTTCGCCTAGGCTC(A/G)CAGCGCGGGAGCGA-3' and the pharmaceutical composition comprising that compound which can be used in treating obesity or muscle deficiencies.
Patent NZ-546543-A (NZ)
Title: Oral drug delivery system
Inventor: ZALA YASHORAJ RUPSINH
IPC: A61K9/20
Filed: 2004-06-30
Abstract: An oral drug delivery system comprising a coated tablet having one or more surfaces, the coated tablet further comprising: a core comprising (i) an active ingredient composition layer comprising at least one active ingredient and a pharmaceutically acceptable excipient; and (ii) a swellable composition layer comprising a swelling agent present in an amount sufficient to rupture the coating from one or more preselected surfaces of the tablet upon contact with an aqueous environment; or - a composition layer comprising an ingredient that is released to cause the coating in the vicinity of one or more preselected surfaces to dissolve, disintegrate or weaken; wherein the swellable composition layer or composition layer comprising an ingredient is located in an immediate vicinity of one or more of the preselected surfaces; and a coating surrounding the core, which comprises a defective coating in the vicinity of one or more of the preselected surfaces, wherein the coating is adapted to be removed partially or fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces.
Patent NZ-546876-A (NZ)
Title: Fibers reinforced cement sheet product and production method thereof
Inventor: FAMY CHARLOTTE
IPC: C04B28/02
Filed: 2004-10-01
Abstract: The disclosure relates to a sheet or board product obtained by the Hatschek process and without autoclaving, which can be used as a weatherboard, cladding element or partition element in a building, wherein the product comprising between 18% and 55% of at least one cement, between 30% and 70% calcium carbonate, and synthetic fibers.
Patent NZ-548821-A (NZ)
Title: Antibodies against clostridium difficile toxins and uses thereof
Inventor: AMBROSINO DONNA
IPC: C12N5/06
Filed: 2005-02-04
Abstract: Disclosed is an isolated human monoclonal antibody or antigen binding portion thereof that specifically binds to Clostridium difficile toxin A and neutralises toxin A in vitro or in vivo. The disclosed antibody protects from or inhibits C. difficile-mediated colitis in a subject; antibiotic-associated colitis in a subject; C. difficile-mediated pseudomembranous colitis (PMC) in a subject; C. difficile-mediated diarrhea in a subject; and inhibits relapse of C. difficile-mediated disease.
Patent NZ-549028-A (NZ)
Title: A stirrup that directed the riders toe in towards the ridden animal and will not catch a foot if the rider inadvertently dismounts
Inventor: WALDRON ALLAN CHARLES
Filed: 2006-08-07
Abstract: A rigid horse riding stirrup is disclosed that assists a novice rider to position their toes correctly and not be caught by the stirrup if they dismount inadvertently. The stirrup comprises: a receptacle for snugly receiving at least the front of a rider's footwear, the receptacle including i) an upper portion that includes a fastening feature for suspension of the stirrup by a stirrup leather, ii) a nose portion for locating a riders footwear around the periphery of a rider's footwear and defining a peak, which in use corresponds to a toe portion of a rider's footwear, iii) a base for vertically supporting a rider's footwear in use, and iv) at least one side wall portion extending between the upper portion and base and nose portion. The receptacle is configured to present an opening towards the back of the horse, to receive a rider's footwear. The nose portion is configured to encourage the positioning of the rider's toes in a direction towards the horse flank and front.
Patent NZ-549543-A (NZ)
Title: Authentication between device and portable storage for digital rights management ( DRM )
Inventor: LEE BYUNG-RAE
IPC: H04L9/30
Filed: 2005-02-25
Abstract: A method for performing authentication between a device and a portable storage is provided. The method comprises the steps of: transmitting a first key to the portable storage, receiving a third key and a first encrypted random number obtained by encrypting a first random number using the first key from the portable storage and decrypting the first encrypted random number using a second key related with the first key, generating a second encrypted random number by encrypting a second random number using the third key and transmitting the second encrypted random number to the portable storage, and generating a session key using the first random number and the second random number. The method provided may be performed by the device or by the portable storage. A portable storage for use with the invention is also provided.
Patent NZ-561363-A (NZ)
Title: Retortable packaging film with grease-resistance comprising at least two layers, a heat seal layer comprising an alpha-olefin compolymer, and a grease-resisistant layer
Inventor: BEKELE SOLOMON
IPC: B32B27/32
Filed: 2006-03-16
Abstract: Disclosed is a retortable multilayer packaging film comprising: (A) a crosslinked heat seal layer comprising a C2-3/C3-20 alpha-olefin copolymer, the heat seal layer being an outer layer; (B) a crosslinked grease-resistant layer comprising a crystalline anhydride-grafted C2-3/C6-20 alpha-olefin copolymer having a density of from 0.93 g/cc to 0.97 g/cc, and optionally at least one member selected from the group consisting of (i) a crystalline C2-3/butene copolymer having a density of at least 0.92 g/cc, (ii) ionomer resin and (iii) ethylene/unsaturated acid copolymer; and (C) an O2-barrier layer, With the grease-resistant layer being between the heat seal layer and the O2-barrier layer.
Patent NZ-564913-A (NZ)
Title: Novel cyclohexenone compounds from antrodia camphorata and application thereof
Inventor: LIU SHENG-YUN
Filed: 2008-01-04
Abstract: Disclosed is a compound of formula (1) wherein X and Y can be oxygen or sulfur, R1, R2 and R3 are each a hydrogen atom, methyl or (CH2)m-CH3, and m=1-12, n=1-12. Also disclosed are a pharmaceutical composition comprising a compound of formula (1) and the use of the compound or composition for treating breast, hepatic and prostate cancers.
Patent NZ-572604-A (NZ)
Title: A resealable closure for a container
Inventor: ORFALI GEORGE
IPC: B44D3/12
Filed: 2008-11-06
Abstract: A resealable closure (10) for an open topped container (12), such as a can made from plastic for containing a liquid such as paint. The container includes an opening defined by a rim (16) and has a radially outward formation (18) adjacent to the rim. The closure includes a substantially rigid plastic cover (22) having a peripheral portion (24) for sealingly engaging the rim and a flexible elastomeric ring (28) joined to the plastic cover that defines an outer skirt (34) for the closure. The elastomeric ring includes an element (30) for engaging the radially outward formation of the container to retain the peripheral portion of the plastic cover in sealed engagement on the rim. The skirt is manually manipulable for removal of the closure from the container when the closure is assembled thereon.
Patent NZ-573818-A (NZ)
Title: Hepatocyte growth factor (hgf) binding proteins
Inventor: WINSTON WILLIAM M
IPC: A61K39/00
Filed: 2007-06-01
Abstract: Disclosed is an isolated binding protein that binds human hepatocyte growth factor (HGF), comprising: (a) an immunoglobulin heavy chain variable region comprising the structure CDRH1-CDRH2-CDRH3, wherein (i) CDRHl comprises amino acid sequence SEQ ID NO. 15, (ii) CDRH2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO. 204 and SEQ ID NO. 205, and (iii) CDRH3 comprises amino acid sequence SEQ ID NO. 17, and (b) an immunoglobulin light chain variable region comprising the structure CDRLl-CDRL2-CDRL3, wherein (i) CDRLl comprises amino acid sequence SEQ ID NO. 18, (ii) CDRL2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO. 19 and SEQ ID NO. 206, and (iii) CDRL3 comprises amino acid sequence SEQ ID NO. 20, wherein the immunoglobulin heavy chain variable region and the immunoglobulin light chain variable region together define a single binding site for binding human HGF. Also disclosed is the use of the binding protein in the preparation of a medicament for inhibiting or reducing proliferation of a tumor cell.
Patent NZ-587678-A (NZ)
Title: Rheumatoid Arthritis treatment by Human Antibodies that Bind Human TNFa
Inventor: SALFELD JOCHEN G
IPC: C12N15/28
Filed: 1997-02-10
Abstract: Provided is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFá with a Kd of 1 x 10-8 M or less and a Koff rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon resonance, and neutralizes human TNFá cytotoxicity in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less; in combination with a non-steroidal anti-inflammatory drug, which can be used for the treatment of rheumatoid arthritis. Further provided are amino acid sequences of suitable antibodies and their CDRs.